Physician profile
John Heffernan
NPI 1649243643
$8,852.19
in general payments reported to CMS, 2019-2025
56 companies · $1,182 in 2025
The $1,182 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,721 · 2020: $811 · 2021: $1,063 · 2022: $1,304 · 2023: $1,446 · 2024: $1,325 · 2025: $1,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,853 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,853.44 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,420.47 | 2019-2024 | Xtandi, Myrbetriq, Veozah |
| Janssen Biotech, INC. | $994.51 | 2019-2024 | Erleada, Balversa, Akeega |
| Pfizer INC. | $677.60 | 2019-2022 | |
| C. R. Bard, INC. & Subsidiaries | $565.15 | 2019-2025 | Bard Urinary Drainage Bag |
| Bayer Healthcare Pharmaceuticals INC. | $519.78 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $391.74 | 2023-2025 | Gemtesa |
| Ferring Pharmaceuticals INC. | $294.76 | 2019-2025 | Adstiladrin |
| Myriad Genetic Laboratories, INC. | $259.86 | 2022-2025 | Prolaris |
| Endo Pharmaceuticals INC. | $251.42 | 2019-2024 | Aveed, Xiaflex |
| Antares Pharma, INC. | $222.73 | 2019-2025 | Xyosted |
| Boston Scientific Corporation | $217.13 | 2019-2023 | Moses 550 D\F\L |
| Procept Biorobotics Corporation | $205.10 | 2023-2025 | Aquabeam Robotic System |
| Urogen Pharma, INC. | $196.35 | 2021-2025 | |
| Telix Pharmaceuticals | $191.02 | 2023-2024 | Illuccix |
| Merck Sharp & Dohme LLC | $160.96 | 2020-2025 | Lynparza, Keytruda, Welireg |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Heffernan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.